Enzymotec, an Israel-based supplements and medicine maker backed by Mexico-based food and enzyme conglomerate Arancia Industrial, is reportedly planning to float on the Nasdaq stock exchange at a $200m market capitalization, according to news provider Globes.
Enzymotec’s other investors include Kibbutz Maanit’s Galam, Ofer Hi-Tech, GlenRock Israel and Millennium Material Technologies Fund.
Enzymotec was founded in 1998 at Ofer Hi-Tech’s Naiot Venture Accelerator and is profitable, Globes added.
Globes said other Israeli life sciences companies were also planning their US initial public offering, including Kamada, Alcobra and Home Skinovations.